Skip to content

BIOSPECIFICS TECHNOLOGIES CORP: 10-Q filed 2012-08-09

What BIOSPECIFICS TECHNOLOGIES CORP reported in its quarterly report filed 2012-08-09 (fiscal Q2 2012): 30 published measures, 86 facts as tagged in accession 0001140361-12-035961.

This filing

Form
10-Q (quarterly report)
Filed
2012-08-09
Fiscal period
fiscal Q2 2012
Accession
0001140361-12-035961 on SEC EDGAR

Values are as tagged in this filing. A later filing can restate them; each measure links to its history page, which shows the latest-filed value per period. All BIOSPECIFICS TECHNOLOGIES CORP filings.

Reported measures

Total assets

Resources recognized on the balance sheet. Book assets are not the market value of the business.

PeriodValueUnitDays
At 2012-06-3017,486,662USD
At 2011-12-3116,265,073USD

Stockholders equity

The reported residual interest after liabilities. It is an accounting amount, not market capitalization.

PeriodValueUnitDays
At 2012-06-3016,151,219USD
At 2011-12-3114,872,314USD

Cash and cash equivalents

Cash and qualifying short-term liquid investments under the filer’s accounting policy. Restricted cash and longer-term investments may be reported separately.

PeriodValueUnitDays
At 2012-06-303,788,173USD
At 2011-12-313,196,831USD
At 2011-06-305,020,547USD
At 2010-12-312,470,852USD

Net income or loss

Reported profit or loss for the period. Check the filing for attribution, exceptional items and discontinued operations before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-30666,682USD91
2012-01-01 to 2012-06-301,409,072USD182
2011-04-01 to 2011-06-302,569,341USD91
2011-01-01 to 2011-06-306,260,464USD181

Operating cash flow

Cash generated or used by operating activities. Working-capital timing can make this differ substantially from reported income.

PeriodValueUnitDays
2012-01-01 to 2012-06-302,397,194USD182
2011-01-01 to 2011-06-302,337,053USD181

Financing cash flow

Net cash from financing activities, including borrowing, repayments and transactions with owners. A positive amount does not establish operating profitability.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-305,852USD182
2011-01-01 to 2011-06-30212,642USD181

Investing cash flow

Net cash from investing activities, including asset purchases, disposals and investment transactions. This differs from capital expenditure payments alone.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-1,500,000USD182
2011-01-01 to 2011-06-300USD181

Retained earnings or deficit

Accumulated undistributed earnings or deficit at the reporting date. This balance is not cash available for distribution.

PeriodValueUnitDays
At 2012-06-30-1,882,832USD
At 2011-12-31-3,291,904USD

Basic weighted-average shares

Time-weighted shares used for basic earnings per share. This denominator differs from shares outstanding at a single reporting date.

PeriodValueUnitDays
2012-04-01 to 2012-06-306,343,356shares91
2012-01-01 to 2012-06-306,339,930shares182
2011-04-01 to 2011-06-306,354,135shares91
2011-01-01 to 2011-06-306,324,168shares181

Diluted weighted-average shares

Weighted-average shares used for diluted earnings per share. Potential shares are included under the applicable dilution rules, not simply added to outstanding shares.

PeriodValueUnitDays
2012-04-01 to 2012-06-306,971,687shares91
2012-01-01 to 2012-06-306,984,258shares182
2011-04-01 to 2011-06-307,174,568shares91
2011-01-01 to 2011-06-307,158,024shares181

Basic earnings per share

Reported earnings or loss per basic common share or unit. Inspect attribution, share classes and restatements before comparing periods. This is not a market return.

PeriodValueUnitDays
2012-04-01 to 2012-06-300.11USD/shares91
2012-01-01 to 2012-06-300.22USD/shares182
2011-04-01 to 2011-06-300.4USD/shares91
2011-01-01 to 2011-06-300.99USD/shares181

Diluted earnings per share

Reported earnings or loss per share under dilution rules. Antidilutive instruments may be excluded. A diluted value can equal the basic value without implying no potential dilution.

PeriodValueUnitDays
2012-04-01 to 2012-06-300.1USD/shares91
2012-01-01 to 2012-06-300.2USD/shares182
2011-04-01 to 2011-06-300.36USD/shares91
2011-01-01 to 2011-06-300.87USD/shares181

Income tax expense or benefit

Current and deferred income tax expense or benefit for continuing operations. This accounting expense differs from cash taxes paid.

PeriodValueUnitDays
2012-04-01 to 2012-06-30390,651USD91
2012-01-01 to 2012-06-30906,228USD182
2011-04-01 to 2011-06-30781,835USD91
2011-01-01 to 2011-06-30-2,757,405USD181

Share-based compensation expense

Reported noncash expense for share-based payment arrangements. Noncash treatment does not mean the awards have no economic cost to shareholders.

PeriodValueUnitDays
2012-01-01 to 2012-06-30175,685USD182
2011-01-01 to 2011-06-30264,907USD181

Operating income or loss

Operating revenue less operating expenses for the reporting period. It excludes items outside the reported operating result and is not free cash flow.

PeriodValueUnitDays
2012-04-01 to 2012-06-301,047,562USD91
2012-01-01 to 2012-06-302,296,036USD182
2011-04-01 to 2011-06-303,320,009USD91
2011-01-01 to 2011-06-303,455,332USD181

Current assets

Assets classified as current under the normal operating cycle or one-year boundary. Not all current assets can be converted immediately into cash.

PeriodValueUnitDays
At 2012-06-3012,706,103USD
At 2011-12-3113,086,503USD

Current liabilities

Obligations classified as current under the operating-cycle or one-year boundary. The balance includes more than short-term borrowing.

PeriodValueUnitDays
At 2012-06-301,093,488USD
At 2011-12-311,116,239USD

Net current accounts receivable

Current customer receivables after the allowance for credit loss. The balance is not cash collected or a guarantee of collection.

PeriodValueUnitDays
At 2012-06-302,820,845USD
At 2011-12-313,236,917USD

Common-stock repurchase payments

Cash paid to reacquire common stock during the period. This is not an authorization limit or a direct measure of the net change in share count.

PeriodValueUnitDays
2012-01-01 to 2012-06-30485,904USD182
2011-01-01 to 2011-06-30206,347USD181

Research and development expense

Research and development costs recognized as expense. Capitalization policies and acquired projects can make this differ from total cash invested in development.

PeriodValueUnitDays
2012-04-01 to 2012-06-30404,346USD91
2012-01-01 to 2012-06-30653,898USD182
2011-04-01 to 2011-06-30270,799USD91
2011-01-01 to 2011-06-30482,865USD181

Additional paid-in capital

Capital contributed above par value under this concept. It records historical contributions, not the current value of the equity or cash on hand.

PeriodValueUnitDays
At 2012-06-3020,404,909USD
At 2011-12-3120,049,196USD

Net intangible assets excluding goodwill

Intangible assets other than goodwill after amortization and impairment. Internally developed intangibles are usually not recognized, so this understates what a company relies on.

PeriodValueUnitDays
At 2012-06-30225,193USD
At 2011-12-31190,416USD

Prepaid expenses and other current assets

Prepayments and other current assets grouped under this concept. The balance is not cash and its composition differs by filer.

PeriodValueUnitDays
At 2012-06-30219,481USD
At 2011-12-3198,234USD

Pre-tax income or loss from continuing operations

Income or loss from continuing operations before income taxes and noncontrolling interests. It excludes discontinued operations and is not net income.

PeriodValueUnitDays
2012-04-01 to 2012-06-301,057,333USD91
2012-01-01 to 2012-06-302,315,300USD182
2011-04-01 to 2011-06-303,351,176USD91
2011-01-01 to 2011-06-303,503,059USD181

Comprehensive income or loss

Net income plus other comprehensive income after tax. It includes unrealized items that net income excludes and is not a cash measure.

PeriodValueUnitDays
2012-04-01 to 2012-06-30666,682USD91
2012-01-01 to 2012-06-301,409,072USD182
2011-04-01 to 2011-06-302,569,341USD91
2011-01-01 to 2011-06-306,260,464USD181

General and administrative expense

General and administrative costs reported under this concept, separate from selling expense. Filers group overhead differently, so compare presentation before comparing companies.

PeriodValueUnitDays
2012-04-01 to 2012-06-301,149,926USD91
2012-01-01 to 2012-06-302,238,648USD182
2011-04-01 to 2011-06-301,418,016USD91
2011-01-01 to 2011-06-302,927,542USD181

Depreciation, depletion and amortization

Combined depreciation, depletion and amortization for the period. A noncash allocation of asset cost, not a measure of maintenance spending.

PeriodValueUnitDays
2012-01-01 to 2012-06-3029,019USD182
2011-01-01 to 2011-06-3021,220USD181

Amortization of intangible assets

Amortization recognized on finite-lived intangible assets. It follows acquisition accounting and does not indicate the intangibles are losing usefulness at that rate.

PeriodValueUnitDays
2012-01-01 to 2012-06-3029,000USD182
2011-01-01 to 2011-06-3021,000USD181

Nonoperating income or expense

Total nonoperating income or expense, which can include interest, investment results and other items. A positive value is not operating profit.

PeriodValueUnitDays
2012-04-01 to 2012-06-309,771USD91
2012-01-01 to 2012-06-3019,264USD182
2011-04-01 to 2011-06-3031,167USD91
2011-01-01 to 2011-06-3047,727USD181

Change in accounts receivable

The cash flow adjustment for the change in receivables during the period. A positive value under this concept means receivables grew and reduced operating cash flow.

PeriodValueUnitDays
2012-01-01 to 2012-06-30-416,072USD182
2011-01-01 to 2011-06-30-1,108,734USD181

Inspect the source

Entity
BIOSPECIFICS TECHNOLOGIES CORP / CIK 0000875622
Captured
SEC response SHA-256
b1d443fa8a2de5e07d7cbcf40e33944d546011c718a394f04bbb863281862def

Current SEC company facts · Download the original response snapshot (gzip) · Download the selected JSON

Every published concept a filing tagged, with the periods it covered, as reported in that filing at capture time. Forms 10-K, 10-K/A, 10-Q, 10-Q/A, 20-F, 20-F/A, 40-F, 40-F/A. A filing page needs at least 8 published concepts. Later filings can restate these values; the company history pages show the latest-filed value per period.

Public company accounting reference, not market prices, returns, an investment recommendation, or ALPHAC performance. Validate a separately constructed return series with the validation API; accounting values are not returns.

Use this in research

A financial period ends before its results become public. Use the filing date as a minimum availability boundary, inspect amendments, and retain the original filing vintage when testing historical signals. This latest-filed selection can contain information unavailable at the time.

These pages do not supply prices, total-return histories, corporate-action adjustments or a tradable universe. Build those inputs separately before evaluating a strategy. A profitable backtest can still reflect selection bias or costs that were left out.

Research methodology · Execution and cost assumptions · Check backtest overfitting

Build with the open-source tools

Use these accounting records as inspectable inputs. When you have constructed a return series, the validation tools can help test its statistical evidence and preserve the result with its limitations.

Read the published dataset with Python
import json
from urllib.request import urlopen

with urlopen("https://canlicapital.com/company-data/0000875622.json") as response:
    record = json.load(response)
print(record["fetched_at"])
print(record["policy"])
for concept in record["concepts"]:
    print(concept["tag"], next(iter(concept["observations"])))